Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Monday, 16 June 2025 01:14 AM	Adani-Ports1399.55	Asian-Paints2236.85	Axis-Bank1213.30	Bajaj-Finance939.85	Bajaj-Finserv2024.00	Bharti-Airtel1862.45	Eternal-Ltd251.05	HCL-Technologies1727.00	HDFC-Bank1937.35	Hind-Unilever2324.15	ICICI-Bank1422.75	IndusInd-Bank822.75	Infosys1631.00	ITC417.25	Kotak-Mah-Bank2138.65	Larsen-and-Toubro3634.95	M-and-M3022.15	Maruti-Suzuki12531.95	Nestle-India2385.80	NTPC332.60	Power-Grid-Corpn288.10	Reliance-Industr1437.20	St-Bk-of-India792.30	Sun-PharmaInds1677.90	Tata-Motors684.65	Tata-Steel153.80	TCS3506.80	Tech-Mahindra1703.00	Titan-Company3433.05	UltraTech-Cem11441.00
15 mins delay SENSEX 81,770.51 [651.91]	-5.70 -0.41%	21.55 0.97%	7.35 0.61%	6.43 0.69%	13.10 0.65%	20.30 1.10%	1.90 0.76%	32.15 1.90%	20.10 1.05%	5.05 0.22%	6.55 0.46%	6.20 0.76%	29.45 1.84%	3.35 0.81%	27.85 1.32%	46.70 1.30%	16.15 0.54%	120.50 0.97%	9.30 0.39%	0.60 0.18%	2.40 0.84%	9.55 0.67%	-0.10 -0.01%	-10.80 -0.64%	-27.40 -3.85%	1.60 1.05%	59.70 1.73%	44.05 2.66%	9.50 0.28%	220.30 1.96%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Alembic Pharma receives USFDA final approval for Bosutinib tablets

30-May-25 15:42Hrs IST

Bosutinib tablets are indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who have shown resistance or intolerance to prior therapy.

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Bosulif Tablets, marketed by PF Prism C.V. (Pfizer).

According to IQVIA, Bosutinib Tablets have an estimated market size of $ 291 million for the twelve months ending March 2025.

Alembic has a cumulative total of 223 ANDA approvals (200 final approvals and 23 tentative approvals) from USFDA.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.

The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.

The counter rose 0.97% to Rs 1,015.30 on the BSE.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

A Muthoot M George Enterprise